In October of 2025, parents in Chhindwara district in Madhya Pradesh, watched their children come down with what looked like an ordinary cold - and then, within days, turned into kidney failure. By the time investigators traced the real cause, at least two dozen children were dead. The culprit wasn’t a rare virus. It was a cough syrup that was nearly half industrial antifreeze, which is toxic to humans.
It is the newest chapter in a story India’s drug regulators have been writing, and trying to rewrite, for decades.
India is, by volume, the third-largest pharmaceutical producer in the world, supplying roughly a fifth of all generic medicines consumed on Earth. It is also home to one of the most uneven quality-assurance systems among major drug-exporting nations, a regulator built for a fraction of the industry it oversees, its testing net that catches thousands of bad batches every year without anyone being quite sure how many it misses, and a wave of factory closures now sweeping through the small manufacturers who can’t afford to catch up.
This isn’t a hidden problem. It’s a known, actively contested one - which in some ways makes it more alarming, not less.
By the numbers
- 10,500+ pharmaceutical manufacturing units in India
- 8 CDSCO zonal offices, 7 sub-zonal offices, 16 port offices - the entire central inspection apparatus
- 116,323 drug samples tested nationwide in 2024-25; 3,104 failed quality standards
- ~8,500 small and mid-sized manufacturers facing a make-or-break GMP deadline; only ~1,700 were compliance-ready as of December 2025
- 24+ children dead in a single Indian district in October 2025 from a contaminated cough syrup
Fault Line 1: A Detection System That Can’t See the Whole Picture
Official numbers suggest the problem is small. In 2024-25, CDSCO and state authorities tested 116,323 drug samples nationwide; 3,104 (2.7%) were declared “Not of Standard Quality” (NSQ), and 245 (0.2%) were spurious or adulterated. On paper, that’s a 97%-plus pass rate - reassuring, until you look at the trend underneath it.
| Year | Samples Tested | NSQ | Spurious/Adulterated | NSQ Rate |
|---|---|---|---|---|
| 2020-21 | 84,874 | 2,652 | 263 | 3.1% |
| 2021-22 | 88,844 | 2,545 | 379 | 2.9% |
| 2022-23 | 96,713 | 3,053 | 424 | 3.2% |
| 2023-24 | 106,150 | 2,988 | 282 | 2.8% |
| 2024-25 | 116,323 | 3,104 | 245 | 2.7% |
Source: Lok Sabha data, Ministry of Health & Family Welfare
Testing volume climbed nearly 37% over five years. The failure rate barely moved. That’s not necessarily a quality success story - it can just as easily mean the same proportion of bad medicine is slipping through every single year, no matter how much harder the system looks. Regulators themselves have acknowledged the ambiguity: when NSQ reports more than doubled in 2025, officials attributed the jump not to declining quality but to states finally testing and reporting more aggressively than before - a tacit admission that earlier figures were undercounts.
What the data cannot tell you - and what the original framing of this story overreached on - is how many actual doses of bad medicine are in patients’ hands at any given moment. A 2.7% sample-failure rate is not the same as “2.7% of India’s medicine supply,” and treating it as such is a leap the numbers don’t support. The honest fault line here isn’t the failure rate itself; it’s that nobody - regulators, researchers, or industry - has a reliable way to convert “what we caught in spot checks” into “what’s actually circulating.”
Fault Line 2: A Regulator Built for a Fraction of the Industry
CDSCO’s central inspection machinery consists of 8 zonal offices, 7 sub-zonal offices, 16 port offices, and 8 testing laboratories nationwide. That apparatus is responsible - alongside state drug control departments - for an industry of more than 10,500 manufacturing units. The math alone explains why most hands-on inspection work falls to chronically stretched state authorities, not the centre.
That strain isn’t a new discovery. A peer-reviewed study published in the Journal of Pharmaceutical Policy and Practice found that in Maharashtra - home to one of India’s largest pharmaceutical hubs - 55% of sanctioned drug inspector posts were vacant as of 2009-10, producing an 83% shortfall against the staffing levels recommended by the government’s own Mashelkar Committee. The same study found that fewer than a quarter of legally required manufacturing and sales inspections were actually being carried out, and noted that government committees had been flagging the same structural weaknesses - for over four decades.
The current government is visibly trying to close that gap: in mid-2026, the UPSC opened recruitment for 186 new Drug Inspector posts under CDSCO alone - one of the largest single hiring drives in the regulator’s history. Whether 186 new inspectors can meaningfully cover 10,500-plus manufacturing units, spread across 28 states and 9 union territories, is the open question hanging over the entire reform effort.
Fault Line 3: The Schedule M Reckoning
The most consequential change to India’s drug-quality rulebook in 35 years took effect on December 28, 2023, when the Ministry of Health revised Schedule M of the Drugs and Cosmetics Rules - overhauling Good Manufacturing Practice (GMP) requirements to bring them closer to WHO-GMP standards, with new mandates covering air handling, cleanrooms, quality risk management, and validated documentation.
Large manufacturers (turnover above ₹250 crore) had to comply by mid-2024. Small and mid-sized manufacturers - the MSMEs that make up roughly 8,500 of India’s 10,500 pharma units - were given until December 31, 2025, with unified enforcement and joint CDSCO-state inspections beginning January 1, 2026. The Drugs Controller General of India publicly rejected industry pleas for a further extension, calling the deadline final.
The result is a transition splitting the country in two:
| State | Compliance Picture |
|---|---|
| Gujarat | 639 of 647 MSME units (98.8%) filed compliance plans - the national benchmark. |
| Maharashtra, Andhra Pradesh, Telangana | Described by industry executives as showing "good participation". |
| Himachal Pradesh | Only 116 of 655+ drug units initiated upgrades; 144 units - 36% of the state's ~400 MSMEs - had already shut down by mid-2025; a single monthly drug alert found 37% of samples from Himachal-based manufacturers failed quality checks. |
| Nationally | Of roughly 6,500 MSMEs required to upgrade, only ~1,700 (26%) had submitted gap-analysis plans by the deadline; nearly 4,300 had done nothing, leaving them exposed to closure once 2026 inspections began. |
Himachal Pradesh - long known as one of India’s biggest pharmaceutical manufacturing clusters, producing roughly a third of the country’s medicines out of hubs like Baddi-Barotiwala-Nalagarh - is, by every available metric, the epicentre of this transition’s casualties. Gujarat is the proof that compliance at scale is achievable. The gap between the two states is the clearest evidence in the entire story that this is a solvable regulatory problem with wildly uneven execution - not an unaddressed one.
Fault Line 4: When the Gap Goes Global - and Comes Home
The consequences of this gap have not stayed inside India’s borders, and recently, they haven’t stayed in the past either.
In October 2022, the WHO issued a global medical product alert after four cough syrups made by Maiden Pharmaceuticals - contaminated with diethylene glycol and ethylene glycol, toxic industrial chemicals - were linked to 70 child deaths in The Gambia. Within months, Uzbekistan reported a near-identical pattern: contaminated syrup from another Indian manufacturer, Marion Biotech, was implicated in the deaths of roughly 65 children. Both cases triggered the same diethylene glycol contamination pathway - a substitution of cheap industrial solvent for pharmaceutical-grade syrup base that a functioning quality-control system should catch before a single bottle leaves the factory.
Then, in October 2025, the same chemical and the same age group turned up not in an export market, but at home. Investigators in Madhya Pradesh found that Coldrif syrup, made by Sresan Pharmaceuticals in Tamil Nadu, contained diethylene glycol at roughly 48.6% concentration - essentially half antifreeze. At least 24 children died before the syrup was banned nationwide and the WHO issued an international alert covering three separate contaminated products from three separate Indian manufacturers. The company’s factory was sealed; its owner now faces manslaughter charges.
The pattern across all three incidents is identical, which is the most damning detail of all: a single rogue batch, caught only after children were already dying, at a manufacturer small enough to have slipped through routine oversight. This is the throughline connecting every fault line above - sparse inspection coverage, an MSME sector racing (and in many cases failing) to meet new standards, and a testing system that catches problems in arrears rather than in advance.
The Reckoning Ahead
None of this means India’s pharmaceutical industry is rotten at the core - the same country that supplies 60% of UNICEF’s vaccines and a fifth of the world’s generic medicines is also the one forcing through the most disruptive quality overhaul its industry has seen in a generation, against fierce and well-organized resistance from the manufacturers it will hurt most.
But “the pharmacy of the world” has spent decades tolerating a manufacturing base whose quality floor sat below WHO guidelines, and the bill for that tolerance is now coming due in real time - in factory closures in Himachal Pradesh, in a 186-post hiring drive at CDSCO, and in small graves in Chhindwara. The fault lines were never hidden. They were priced in. What’s changed is that, for the first time in 35 years, someone is finally calling the loan.
📚 Sources (Click to Expand)
1. 2025 India Cough Syrup Crisis
- Wikipedia — 2025 India cough syrup crisis
- CNN — “WHO issues warning over contaminated cough syrup in India after multiple child deaths” (Oct 14, 2025)
- The Bureau of Investigative Journalism — “Why do children keep dying from toxic cough syrup?” (Oct 13, 2025)
2. Indian Pharmacy Market
- IBEF — “Pharma Companies in India”
- Wikipedia — “Pharmaceutical industry in India”
3. Manufacturing Units Data
- IBEF — “Pharmaceutical Companies in India Driving Innovation”
- NewKerala — “India Pharma: 3rd by Volume, 11th by Value, $130B by 2030”
4. CDSCO Infrastructure
5. Quality Testing Statistics
- Asianet Newsable — “Drug Quality in India: Govt data reveals thousands of substandard drugs”
6. MSME GMP Transition
- Business Standard — “Just 1 in 4 MSME pharma units set for GMP transition”
7. Lok Sabha Data
- Medical Dialogues — “Over 14,300 Drug Samples Fail Quality Tests in Five Years: Minister”
8. Sampling Guidelines
9. Inspector Shortages
- Kadam AB, et al. — “Correcting India’s chronic shortage of drug inspectors to ensure the production and distribution of safe, high-quality medicines.”
10. Recruitment Drive
11. Schedule M Revision
- India Briefing — “India Extends GMP Compliance Deadline to December 2025”
12. Enforcement Stance
- Amzor Healthcare — “DCGI Affirms Revised Schedule M Norms Will Be Enforced as Scheduled”
13. State-Level Compliance
- Business Standard — “Just 1 in 4 MSME pharma units set for GMP transition as deadline nears”
14. Himachal Pradesh Impact
- The Tribune — “Small pharma units in Himachal shut shop as revised Schedule M norms tighten compliance net”
- The Tribune — “Unable to upgrade, 144 pharma units in Himachal Pradesh close operations”
15. Gambia Incident
- Wikipedia — “Gambia cough syrup scandal”
- VOA Africa — “Grief, Outrage in Gambia Over Cough Syrup Deaths”
